---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-108583"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:39:52.589647+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Therapeutics adopts post-IPO charter authorizing 175M common shares and eliminating written consent

## Summary
- Fifth amended charter effective Oct 15, 2024; authorizes 175M shares of common stock and 25M shares of undesignated preferred stock.
- Eliminates all references to previously existing series of preferred stock and removes stockholder ability to act by written consent.
- Amended bylaws establish procedures for stockholder proposals and director nominations, and modify officer/director indemnification provisions.
- Charter and bylaw changes were approved by board and stockholders prior to IPO consummation.

## SEC filing metadata
- accession: 0001104659-24-108583
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/0001104659-24-108583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-108583
- JSON: https://secwatch.observer/filing/0001104659-24-108583.json
- Plain text: https://secwatch.observer/filing/0001104659-24-108583.txt

## Key facts
- Governance Changes
  Camp4 Therapeutics Corp: Adopted amended and restated bylaws to establish procedures for stockholder proposals and director nominations, modify indemnification provisions, and conform to the amended charter (effective 2024-10-15).
  - Change: bylaw amendment
  - Effective: 2024-10-15
  source text: On October 15, 2024, in connection with the consummation of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors and stockholders, became effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/0001104659-24-108583-index.htm
- Governance Changes
  Camp4 Therapeutics Corp: Filed fifth amended and restated certificate of incorporation to increase authorized common stock, eliminate references to existing preferred, authorize undesignated preferred stock, and eliminate stockholder action by written consent (effective 2024-10-15).
  - Change: charter amendment
  - Effective: 2024-10-15
  source text: On October 15, 2024, in connection with the consummation of the initial public offering (the “IPO”) of shares of common stock, par value $0.0001 per share (“Common Stock”), of CAMP4 Therapeutics Corporation (the “Company”), the Company filed a fifth amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware, which became effective upon filing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/0001104659-24-108583-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.